BioMedNewsBreaks

MondayMay 10, 2021 1:35 pm

BioMedNewsBreaks – InnerScope Hearing Technologies Inc. (INND) to Present at Diamond Equity Research Emerging Growth Virtual Conference

InnerScope Hearing Technologies (OTC: INND), an emerging and disruptive leader in the direct-to-consumer (“DTC”) hearing technology space, today announced that its CEO Matthew Moore was invited to present at the Diamond Equity Research Emerging Growth Invitation Virtual Conference. InnerScope will be the only OTC: Pink company invited to present alongside NASDAQ-listed companies for the May 11, 2021, virtual conference. Moore is scheduled to host a virtual presentation to institutional investors at 12:20 p.m. ET, during which he will provide an overview of InnerScope’s business as a disruptive leader in the emerging DTC hearing aid device market, expected to be worth…

Continue Reading

MondayMay 10, 2021 12:22 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for May Investor Conferences

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will participate in a number of virtual conferences for the month of May, including the Diamond Equity Emerging Growth Invitational, the Benzinga Small Cap Conference and the CEO Roadshow Webinar Series. Genprex’s CEO and President Rodney Varner will lead the presentations, which will highlight novel gene therapies for cancer and diabetes and upcoming clinical trials in non-small cell lung cancer (“NSCLC”). An archive of the presentations will be available for a period of time following the conferences…

Continue Reading

MondayMay 10, 2021 10:03 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Master Agreement with Leading CRO Clinlogix

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, has entered into a master service agreement with Clinlogix, a contract research organization (“CRO”). The agreement is a key step for initiating and supporting the clinical development of Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program. Tryp noted that Clinlogix has global experience in providing CRO services for the development of novel pharmaceutical products, and the agreement outlines the collaboration between the two companies, as well as other clinical partners, will include medical writing, biostatistical analysis, data management and trial monitoring. The…

Continue Reading

FridayMay 07, 2021 3:58 pm

BioMedNewsBreaks – RYAH Group Inc. Bringing Innovative Tech Solutions to Plant-Based Treatment Market

RYAH Group, a company developing proprietary technology supporting a data-driven approach to health care, understands the value of combining data with analytics, as reflected by the fact that its products merge these two fundamental elements. “The company has created unique products that pair a growing ecosystem of therapeutic plants with top-rated apps, devices and services,” reads a recent article. “RYAH’s easy-to-operate line of products help foster a seamless dose-control experience that generates insightful data, making it simple for doctors, researchers and end-users to hone in on the ideal settings for the best possible treatment outcomes with RYAH Smart Patch, RYAH…

Continue Reading

FridayMay 07, 2021 3:29 pm

BioMedNewsBreaks – Brain Scientific Inc.’s (BRSF) Products Designed to Disrupt EEG Market

Brain Scientific (OTCQB: BRSF), focused on modernizing the brain diagnostic market through cutting-edge technologies, has sought to narrow the wide access-to-neurological-care gap through portable EEGs, teleneurology, on-demand data exchange and AI predictive biomarkers. “By creating cost-efficient, disposable and portable EEGs, BRSF makes neurology care more accessible without putting excess strain on the already overextended neurologist labor pool,” reads a recent article. As a result, the company has directly tackled the shortage of neurologists in the United States. “The company’s commercialized products were designed to disrupt the slow, expensive and cumbersome EEG market with easy-to-use, economical and disposable solutions. These devices…

Continue Reading

FridayMay 07, 2021 3:06 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Leads Research and Manufacture of Beneficial Plant-Based Formulations

Healthy Extracts (OTCQB: HYEX) has continued to strengthen its stronghold in the health and lifestyle industry by researching and manufacturing plant-based formulations offering supplements that are beneficial for heart and nerve health. HYEX has broadened its portfolio through acquisitions of unique assets, BergaMet North America and Ultimate Brain Nutrients (“UBN”). “Healthy Extracts Inc. recently announced positive results of clinical studies for two leading products: BergaMet North America’s HERHEART(TM) and Ultimate Brain Nutrients’ Fuel4Thought(TM) Brain Booster,” reads a recent article. “Duke Pitts, CEO of BergaMet North America, stated that HERHEART(TM) is a natural supplement that is scientifically formulated specifically for women…

Continue Reading

FridayMay 07, 2021 1:48 pm

BioMedNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) i/Blue(TM) Imaging System to Enable More Accurate Tumor Resection

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has made notable strides in its quest to offer innovative technology for visualizing cancer. Designed to address the limitations of both white and blue light cystoscopy procedures, IME’s i/Blue(TM) Imaging System displays real-time white and blue light images on the screen simultaneously. This eliminates the need for the surgeon to switch back and forth between images, as is the case with blue light cystoscopy. On the other hand, it addresses the limitation of the white light cystoscopy, which is notorious for not clearly defining the margins between flat tumor and…

Continue Reading

FridayMay 07, 2021 12:56 pm

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference/Webcast to Discuss Q1 Results, Provide Clinical Pipeline Update

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that it will host a conference call and live webcast to discuss its first quarter 2021 results and provide an update on its clinical pipeline. The event is scheduled to take place at 5:30 p.m. ET on Thursday, May 13, 2021. Interested parties may visit https://ibn.fm/nuO3H to register, as well as join the call by dialing 888-506-0062 (Toll-Free) or 973-528-0016 (International) and entering code: 396394. Participants are asked to dial in approximately five to…

Continue Reading

FridayMay 07, 2021 11:03 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Launches ‘Covid-ID Lab’ POC Pilot Project in Germany

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced its commencement of a pilot project with its rapid COVID-19 PCR test ("Covid-ID Lab") in a point-of-care ("POC") setting in Germany. Covid-ID Lab was recently approved in Europe and offers the accuracy of a PCR test in only 25 minutes. Validated work flows, including mobile collection and processing of patient samples, will be further optimized during the test. XPhyto's clinical partner for the project is Spitzweg Apotheke, a well-known pharmacy in Langen near Frankfurt, Germany, currently running a COVID-19 test center at a clinic, where it also provides special pharmacy…

Continue Reading

ThursdayMay 06, 2021 3:14 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Advancing Solutions for ‘Personalized Medicine at Its Finest’

Predictive Oncology (NASDAQ: POAI) has made several advances in providing cancer treatment solutions. Its subsidiary, TumorGenesis, “specializes in technology that preserves a patient’s unique cancer tissue biological signatures, thereby allowing researchers to study cancer in the laboratory using samples that reflect actual tumors found in a patient,” reads a recent article.  TumorGenesis’ transformational technology enables cell lines from patients to represent more than 90% of ovarian cancer cells, a significant improvement from the existing technologies, which can only represent 1% of ovarian tumor cells. “The result, simply stated, assists health providers in selecting the most effective drug to treat a…

Continue Reading